Navigation Links
Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
Date:2/22/2011

SEATTLE, Feb. 22, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use. Omeros' PDE7 program was founded on the Company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease.  Omeros believes that it also is the first to link PDE7 to any addiction or compulsive behavior, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse (NIDA) and The Michael J. Fox Foundation.

"We are pleased to announce our agreement with Daiichi Sankyo and the additional therapeutic focus of our PDE7 program," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "From the advanced Daiichi compounds we have already selected a clinical candidate, and we expect that addiction will provide us with a faster and less expensive development pathway for our PDE7 program. We are collaborating with NIDA on additional studies that will evaluate our compounds in addiction, and we look forward to working with NIDA to advance this program through the clinic."

PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both movement and addiction. Omeros believes that PDE7 inhibitors could be effective therapeutics for the treatment of movement disorders as well as addiction and compulsive disorders. Omeros has shown in animal models of cocaine addiction that PDE7 inhibitors reduce cocaine self-administration, inhibit relapse induced by cues and stress, and facilitate drug abstinence in previously addicted animals. Importantly, no effect on normal feeding was observed
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Publication of Data From Antifibrinolytic Program
2. Omeros Licenses Novel Antifibrinolytic Agents
3. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
4. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
5. Omeros to Present at the BioCentury NewsMakers Conference
6. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
7. Omeros Successfully Unlocks Orphan GPCRs
8. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
9. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
10. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
11. Daniel K. Spiegelman Elected to Board of Directors of Omeros
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/30/2014)... 30, 2014 Ticket Down reports that ... exhibition match next Saturday at Levi's Stadium. The summer ... fans in the United States due to the fact that so ... every major city. Many of these games were practice games ... past summer. , Levi’s Stadium is a brand new facility that ...
(Date:8/30/2014)... Dayton, OH (PRWEB) August 30, 2014 United ... school’s first fully online degree, the Master of Theological Studies ... completed in 2-3 years, is designed for students who wish ... deepen their understanding and capacity to serve the Church and ... this degree, but now they can attend classes from any ...
(Date:8/30/2014)... Patients suffering from vitiligo can now ... new review published by Daily Gossip. , Vitiligo ... there is no wonder that numerous sufferers search for ... Treatment is one of the most appreciated such methods ... to stop the spread of this disorder immediately, while ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic ... attacks under control with a simple and efficient method. ... this new method as an anxiety recovery program which ... general anxiety related disorders. , What makes this ... it can be accessed by users from the comfort ...
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2
... - Notification of Year End,2007 Earnings Webcast and Conference ... Year End 2007 Earnings Webcast and Conference Call ... listen to this Webcast and Conference Call event, please ... in the live conference call please dial into either,(604) ...
... announced today,that it has initiated coverage on leading Australian ... hand and royalty,revenue alone are equal to roughly US$0.94 ... DCF value for ART621 and you have a premium,of ... without assigning any,value to their current pre-clinical pipeline which ...
... International,Inc. (Nasdaq: CHDX ) (the ,Company,) today announced ... split of all shares of,the Company,s Common Stock, par ... Stockholders of record as of the close of business ... Common Stock for each,share owned on that date in ...
... 1418 passed by full Senate, moves to House, ... allowing the state Medicaid program to expend moneys to ... approved,by a vote of 27 to 3., Currently, ... doesn,t,cover smoking cessation programs in the state,s Medicaid program, ...
... acuity may actually improve , , TUESDAY, March 18 (HealthDay ... head-and-neck cancer patients experience decreases in their physical quality ... of life, says a U.S. study. , In ... head and neck cancer treatment such as feeding tube ...
... scientists have been proclaiming the benefits of exercise. Studies ... in number, examining many health problems ranging from cancer ... Now, a University of Missouri researcher has found direct ... Disease Control that a reduction in daily physical activity ...
Cached Medicine News:Health News:Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx) 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2Health News:Killer stairs? Taking the elevator could be worse for your body 2Health News:Killer stairs? Taking the elevator could be worse for your body 3
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
... Plus Long Instrument for applications ... VERSASTEP™ Plus Long Instrument with ... unique endoscopic entry device that ... It is used to establish ...
... device components are supplied sterile. , ,The ... supplied sterile in 2/3, 5, 7/8, 10 and ... combinations. They are used in conjunction with the ... radially Expandable Sleeve. The 5, 7/8, 10 and ...
BLUNTPORT Plus Single Use Converterless 5 mm - 12 mm Trocar System for Open Laparoscopy....
Medicine Products: